Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 143 Cr.
- Current Price ₹ 87.6
- High / Low ₹ 160 / 75.2
- Stock P/E 10.5
- Book Value ₹ 54.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.68 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | |
| 29 | 53 | 54 | 67 | 88 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 |
| OPM % | 5% | 11% | 13% | 19% | 15% |
| 0 | 0 | 0 | 0 | 4 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% |
| 1 | 4 | 5 | 10 | 14 | |
| EPS in Rs | 8.45 | 8.28 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 | 74 |
| 3 | 3 | 4 | 5 | 30 | 33 | |
| 9 | 22 | 28 | 27 | 10 | 12 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 134 |
| 6 | 7 | 10 | 10 | 12 | 16 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 7 | 52 | 53 |
| 12 | 27 | 37 | 44 | 58 | 66 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 134 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 144 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 |
| ROCE % | 55% | 47% | 57% | 27% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
11 December 2025 - One-on-one analyst meetings on 16 Dec 2025 with AlphaWealth and Swaraj Holding; virtual; no UPSI.
-
Copy of Newspaper Publication
8 December 2025 - Published newspaper ads (Dec 08, 2025) and dispatched postal ballot notice; remote e-voting for shareholder resolution.
-
General Updates
8 December 2025 - Nov 2025 net sales Rs79,311,061 (YoY +24.99%); Apr-Nov 2025 Rs651,909,175 (+27.84%).
-
Shareholders meeting
8 December 2025 - Postal ballot to appoint M/s C.H. Padliya & Co. as statutory auditor; e-voting Dec 9,2025–Jan 7,2026.
-
Statement of deviation(s) or variation(s) under Reg. 32
15 November 2025 - No deviation in utilization of Rs.4,316.11 lakhs IPO proceeds for quarter ended 30-Sep-2025.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar